

Marilyn A Huestis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8204222/marilyn-a-huestis-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213
papers

9,560
citations

55
h-index

86
g-index

219
ext. papers

10,932
ext. citations

4.1
avg, IF

6.6
L-index

#	Paper	IF	Citations
213	Identification of Δ -tetrahydrocannabinol (THC) impairment using functional brain imaging.. <i>Neuropsychopharmacology</i> , 2022 ,	8.7	1
212	Substance use onset in high-risk 9-13 year-olds in the ABCD study.. <i>Neurotoxicology and Teratology</i> , 2022 , 107090	3.9	1
211	Separate and combined effects of alcohol and cannabis on mood, subjective experience, cognition and psychomotor performance: A randomized trial.. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022 , 110570	5.5	1
210	Preliminary Evidence for Cannabis and Nicotine Urinary Metabolites as Predictors of Verbal Memory Performance and Learning Among Young Adults. <i>Journal of the International Neuropsychological Society</i> , 2021 , 27, 546-558	3.1	1
209	Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. <i>Drug Testing and Analysis</i> , 2021 , 13, 539-549	3.5	8
208	A Review of Synthetic Cathinone-Related Fatalities From 2017 to 2020. <i>Therapeutic Drug Monitoring</i> , 2021 , 43, 52-68	3.2	19
207	Combined effect of alcohol and cannabis on simulated driving. <i>Psychopharmacology</i> , 2021 , 1	4.7	5
206	Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties. <i>Drug and Alcohol Dependence</i> , 2021 , 227, 108962	4.9	2
205	Toxicology and Analysis of Psychoactive Tryptamines. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
204	The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020 , 212, 107993	4.9	25
203	Comparative Pharmacokinetics of Δ Tetrahydrocannabinol in Adolescent and Adult Male Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020 , 374, 151-160	4.7	18
202	Acute and residual mood and cognitive performance of young adults following smoked cannabis. <i>Pharmacology Biochemistry and Behavior</i> , 2020 , 194, 172937	3.9	7
201	Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2020 , 44, 651-660	2.9	5
200	Prenatal Tobacco and Cannabis Exposure: Associations with Cortisol Reactivity in Early School Age Children. <i>International Journal of Behavioral Medicine</i> , 2020 , 27, 343-356	2.6	11
199	Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1203-1212	6.1	3
198	Identifying and Quantifying Cannabinoids in Biological Matrices in the Medical and Legal Cannabis Era. <i>Clinical Chemistry</i> , 2020 , 66, 888-914	5.5	16
197	Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study. <i>Translational Psychiatry</i> , 2020 , 10, 71	8.6	22

196 Cannabis **2020**, 389-448

195	Pyrrolidinyll Synthetic Cathinones EPHP and 4F-EPVP Metabolite Profiling Using Human Hepatocyte Incubations. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	1
194	Miniaturized extraction method for analysis of synthetic opioids in urine by microextraction with packed sorbent and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2020 , 1624, 461241	4.5	7
193	Monitoring Perinatal Exposure to Cannabis and Synthetic Cannabinoids. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 194-204	3.2	12
192	Testing Unconventional Matrices to Monitor for Prenatal Exposure to Heroin, Cocaine, Amphetamines, Synthetic Cathinones, and Synthetic Opioids. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 205-221	3.2	9
191	Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. <i>Pharmacology Biochemistry and Behavior</i> , 2020 , 199, 173059	3.9	13
190	Impact of cannabis and low alcohol concentration on divided attention tasks during driving. <i>Traffic Injury Prevention</i> , 2020 , 21, S123-S129	1.8	2
189	Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LC-MS-MS. <i>Journal of Analytical Toxicology</i> , 2020 , 44, 697-707	2.9	19
188	The effect of prenatal adversity on externalizing behaviors at 24 months of age in a high-risk sample: Maternal sensitivity as a moderator. <i>Infant Mental Health Journal</i> , 2020 , 41, 530-542	2.3	1
187	THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis". <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 58, 682-689	5.9	20
186	Validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method to detect cannabinoids in whole blood and breath. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 58, 673-681	5.9	16
185	Prenatal tobacco and marijuana co-use: Sex-specific influences on infant cortisol stress response. <i>Neurotoxicology and Teratology</i> , 2020 , 79, 106882	3.9	3
184	Prenatal exposure to tobacco and marijuana and child autonomic regulation and reactivity: An analysis of indirect pathways via maternal psychopathology and parenting. <i>Developmental Psychobiology</i> , 2019 , 61, 1022-1034	3	6
183	Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. <i>Journal of Psychoactive Drugs</i> , 2019 , 51, 108-117	3.6	8
182	Oral Fluid Drug Testing: Analytical Approaches, Issues and Interpretation of Results. <i>Journal of Analytical Toxicology</i> , 2019 , 43, 415-443	2.9	39
181	Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. <i>Drug and Alcohol Dependence</i> , 2019 , 205, 107641	4.9	21
180	Cannabidiol Adverse Effects and Toxicity. <i>Current Neuropharmacology</i> , 2019 , 17, 974-989	7.6	121
179	New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. <i>Frontiers in Chemistry</i> , 2019 , 7, 109	5	52

178	Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users. <i>Drug Testing and Analysis</i> , 2019 , 11, 968-975	3.5	11
177	Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges. <i>Current Addiction Reports</i> , 2019 , 6, 429-436	3.9	3
176	Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake. <i>Trends in Molecular Medicine</i> , 2018 , 24, 156-172	11.5	32
175	Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2018 , 36, 304-312	2.6	9
174	Drug exposure during pregnancy: analytical methods and toxicological findings. <i>Bioanalysis</i> , 2018 , 10, 587-606	2.1	23
173	Prenatal Risk and Infant Regulation: Indirect Pathways via Fetal Growth and Maternal Prenatal Stress and Anger. <i>Child Development</i> , 2018 , 89, e123-e137	4.9	13
172	Optimization of recombinant Eglucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2018 , 10, 518-529	3.5	15
171	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018 , 157, 27-35	3.5	14
170	Co-use of tobacco and marijuana during pregnancy: Pathways to externalizing behavior problems in early childhood. <i>Neurotoxicology and Teratology</i> , 2018 , 69, 39-48	3.9	3
169	Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. <i>PLoS ONE</i> , 2018 , 13, e0190768	3.7	58
168	Quantification of ethyl glucuronide, ethyl sulfate, nicotine, and its metabolites in human fetal liver and placenta. <i>Forensic Toxicology</i> , 2018 , 36, 102-112	2.6	3
167	Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 367, 543-550	4.7	10
166	Prenatal tobacco and marijuana co-use: Impact on newborn neurobehavior. <i>Neurotoxicology and Teratology</i> , 2018 , 70, 28-39	3.9	10
165	Prenatal exposure to tobacco and cannabis: Effects on autonomic and emotion regulation. <i>Neurotoxicology and Teratology</i> , 2018 , 68, 47-56	3.9	19
164	Additive drug-specific and sex-specific risks associated with co-use of marijuana and tobacco during pregnancy: Evidence from 3 recent developmental cohorts (2003-2015). <i>Neurotoxicology and Teratology</i> , 2018 , 68, 97-106	3.9	11
163	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). <i>Forensic Toxicology</i> , 2017 , 35, 20-32	2.6	30
162	Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration. <i>Journal of Applied Toxicology</i> , 2017 , 37, 922-932	4.1	24
161	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. <i>AAPS Journal</i> , 2017 , 19, 568-577	3.7	19

160	Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ^9 Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration. <i>Clinical Chemistry</i> , 2017 , 63, 647-662	5.5	29
159	Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. <i>Drug and Alcohol Dependence</i> , 2017 , 175, 67-76	4.9	53
158	Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review. <i>Journal of Analytical Toxicology</i> , 2017 , 41, 573-610	2.9	96
157	On-site oral fluid Δ^9 -tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration. <i>Forensic Toxicology</i> , 2017 , 35, 133-145	2.6	8
156	Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells. <i>Archives of Toxicology</i> , 2017 , 91, 3633-3643	5.8	17
155	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. <i>Clinical Chemistry</i> , 2017 , 63, 1008-1021	5.5	36
154	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2017 , 35, 252-262	2.6	7
153	Neuropharmacology of 3,4-Methylenedioxypropylvalerone (MDPV), Its Metabolites, and Related Analogs. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 32, 93-117	3.4	99
152	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. <i>Clinical Chemistry</i> , 2017 , 63, 1753-1763	5.5	9
151	Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users. <i>Psychopharmacology</i> , 2017 , 234, 3431-3442	4.7	20
150	Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses. <i>Drug and Alcohol Dependence</i> , 2017 , 180, 68-75	4.9	28
149	Smoking in Pregnancy and Fetal Growth: The Case for More Intensive Assessment. <i>Nicotine and Tobacco Research</i> , 2017 , 19, 525-531	4.9	18
148	Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health. <i>Clinical Chemistry</i> , 2017 , 63, 1564-1569	5.5	25
147	25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry. <i>Drug Testing and Analysis</i> , 2017 , 9, 680-698	3.5	38
146	Long-term stability of cannabinoids in oral fluid after controlled cannabis administration. <i>Drug Testing and Analysis</i> , 2017 , 9, 143-147	3.5	23
145	Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 101, 239-253	6.1	64
144	Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. <i>Drug Testing and Analysis</i> , 2017 , 9, 905-915	3.5	55
143	Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. <i>Current Neuropharmacology</i> , 2017 , 15, 682-691	7.6	29

142	4-Methoxy-EPVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2016 , 34, 61-75	2.6	40
141	Maternal Buprenorphine Maintenance and Lactation. <i>Journal of Human Lactation</i> , 2016 , 32, 675-681	2.6	26
140	Effects of fetal tobacco exposure on focused attention in infancy. <i>Research in Social and Administrative Pharmacy</i> , 2016 , 45, 1-10	2.9	6
139	Cannabinoids Pharmacology, Abuse, and Addiction 2016 , 1-27		
138	Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. <i>Analytical and Bioanalytical Chemistry</i> , 2016 , 408, 6461-71	4.4	37
137	Reprint of "Adolescent cortical thickness pre- and post marijuana and alcohol initiation". <i>Neurotoxicology and Teratology</i> , 2016 , 58, 78-87	3.9	1
136	Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases. <i>Drug Metabolism Reviews</i> , 2016 , 48, 237-65	7	46
135	Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016 , 1451, 97-106	4.5	5
134	Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2016 , 1453, 34-42	4.5	44
133	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. <i>Drug Testing and Analysis</i> , 2016 , 8, 682-9	3.5	26
132	Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2016 , 30, 1067-78	2.2	49
131	Linear pharmacokinetics of 3,4-methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects. <i>Addiction Biology</i> , 2016 , 21, 339-47	4.6	76
130	Effect of Blood Collection Time on Measured Δ -Tetrahydrocannabinol Concentrations: Implications for Driving Interpretation and Drug Policy. <i>Clinical Chemistry</i> , 2016 , 62, 367-77	5.5	44
129	Oral fluid cocaine and benzoylecgonine concentrations following controlled intravenous cocaine administration. <i>Forensic Science International</i> , 2016 , 260, 95-101	2.6	19
128	In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. <i>AAPS Journal</i> , 2016 , 18, 455-64	3.7	45
127	In vitro, in vivo and in silico metabolic profiling of Epyrrolidinopentiothiophenone, a novel thiophene stimulant. <i>Bioanalysis</i> , 2016 , 8, 65-82	2.1	40
126	High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. <i>Clinical Chemistry</i> , 2016 , 62, 157-69	5.5	62
125	Comparison of (+)- and (-)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 358, 209-15	4.7	3

124	Free and Glucuronide Whole Blood Cannabinoids Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. <i>Clinical Chemistry</i> , 2016 , 62, 1579-1592	5.5	93
123	A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. <i>Journal of Pain Research</i> , 2016 , 9, 587-98	2.9	29
122	Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. <i>Drug Testing and Analysis</i> , 2016 , 8, 779-91	3.5	27
121	Cannabis effects on driving longitudinal control with and without alcohol. <i>Journal of Applied Toxicology</i> , 2016 , 36, 1418-29	4.1	56
120	Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. <i>Drug Testing and Analysis</i> , 2016 , 8, 690-701	3.5	30
119	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. <i>Forensic Toxicology</i> , 2016 , 34, 256-267	2.6	19
118	First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2016 , 408, 4845-56	4.4	34
117	Pharmacodynamic effects and relationships to plasma and oral fluid pharmacokinetics after intravenous cocaine administration. <i>Drug and Alcohol Dependence</i> , 2016 , 163, 116-25	4.9	14
116	Drug Recognition Expert (DRE) examination characteristics of cannabis impairment. <i>Accident Analysis and Prevention</i> , 2016 , 92, 219-29	6.1	31
115	Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior. <i>Neurotoxicology and Teratology</i> , 2016 , 57, 87-94	3.9	6
114	Adolescent cortical thickness pre- and post marijuana and alcohol initiation. <i>Neurotoxicology and Teratology</i> , 2016 , 57, 20-29	3.9	28
113	Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry. <i>AAPS Journal</i> , 2016 , 18, 1489-1499	3.7	55
112	Epigenetic Regulation of Placental NR3C1: Mechanism Underlying Prenatal Programming of Infant Neurobehavior by Maternal Smoking?. <i>Child Development</i> , 2016 , 87, 49-60	4.9	34
111	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. <i>Current Neuropharmacology</i> , 2016 ,	7.6	1
110	The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. <i>Neuropsychopharmacology</i> , 2015 , 40, 1053-63	8.7	102
109	Cannabis effects on driving lateral control with and without alcohol. <i>Drug and Alcohol Dependence</i> , 2015 , 154, 25-37	4.9	137
108	Simultaneous determination of 40 novel psychoactive stimulants in urine by liquid chromatography-high resolution mass spectrometry and library matching. <i>Journal of Chromatography A</i> , 2015 , 1397, 32-42	4.5	92
107	Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices. <i>Drug Metabolism Reviews</i> , 2015 , 47, 124-74	7	79

106	Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol. <i>Forensic Toxicology</i> , 2015 , 33, 260-278	2.6	11
105	Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2015 , 33, 295-310	2.6	55
104	Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA. <i>AAPS Journal</i> , 2015 , 17, 660-77	3.7	85
103	Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. <i>Journal of Analytical Toxicology</i> , 2015 , 39, 580-7	2.9	30
102	Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration. <i>Bioanalysis</i> , 2015 , 7, 2041-56	2.1	20
101	Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography-tandem mass spectrometry. <i>Drug Testing and Analysis</i> , 2015 , 7, 684-94	3.5	41
100	High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. <i>Drug Testing and Analysis</i> , 2015 , 7, 187-98	3.5	36
99	Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. <i>Drug Testing and Analysis</i> , 2015 , 7, 483-93	3.5	27
98	Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. <i>Drug Testing and Analysis</i> , 2015 , 7, 467-74	3.5	28
97	Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 883-97	4.4	105
96	Prenatal tobacco exposure and infant stress reactivity: role of child sex and maternal behavior. <i>Developmental Psychobiology</i> , 2015 , 57, 212-25	3	19
95	Urine Mescaline Screening With a Biochip Array Immunoassay and Quantification by Gas Chromatography-Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 805-11	3.2	2
94	Validation of an ELISA Synthetic Cannabinoids Urine Assay. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 661-93.2	3.2	18
93	Smoked cannabis psychomotor and neurocognitive effects in occasional and frequent smokers. <i>Journal of Analytical Toxicology</i> , 2015 , 39, 251-61	2.9	90
92	Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 4639-48	4.4	14
91	Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol. <i>Clinical Chemistry</i> , 2015 , 61, 850-69	5.5	85
90	Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 423-34	5.9	25
89	Impact of oral fluid collection device on cannabinoid stability following smoked cannabis. <i>Drug Testing and Analysis</i> , 2015 , 7, 114-20	3.5	18

88	Quantification of methylone and metabolites in rat and human plasma by liquid chromatography-tandem mass spectrometry. <i>Forensic Toxicology</i> , 2015 , 33, 202-212	2.6	9
87	Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 1763-80	4.4	93
86	Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology. <i>Drug Testing and Analysis</i> , 2014 , 6, 728-38	3.5	47
85	3,4-Methylenedioxypropylone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. <i>Analytica Chimica Acta</i> , 2014 , 827, 54-63	6.6	37
84	Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine. <i>Forensic Science International</i> , 2014 , 241, 27-34	2.6	42
83	Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2014 , 1327, 105-17	4.5	86
82	Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 1945-55	4.4	29
81	Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. <i>Drug and Alcohol Dependence</i> , 2014 , 144, 12-41	4.9	453
80	Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?. <i>Clinical Chemistry</i> , 2014 , 60, 361-72 ⁵	5.5	29
79	The potential role of oral fluid in antidoping testing. <i>Clinical Chemistry</i> , 2014 , 60, 307-22	5.5	41
78	Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. <i>Clinical Chemistry</i> , 2014 , 60, 631-43	5.5	95
77	Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 4117-28	4.4	33
76	Maternal smoking during pregnancy and infant stress response: test of a prenatal programming hypothesis. <i>Psychoneuroendocrinology</i> , 2014 , 48, 29-40	5	78
75	Quantification of cocaine and metabolites in exhaled breath by liquid chromatography-high-resolution mass spectrometry following controlled administration of intravenous cocaine. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 6213-23	4.4	23
74	Method validation of the biochip array technology for synthetic cannabinoids detection in urine. <i>Bioanalysis</i> , 2014 , 6, 2919-30	2.1	14
73	Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. <i>Bioanalysis</i> , 2014 , 6, 1187-200	2.1	21
72	Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. <i>Drug Testing and Analysis</i> , 2014 , 6, 1002-10	3.5	27
71	Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. <i>Bioanalysis</i> , 2014 , 6, 1471-85	2.1	19

70	Quantification of 11-nor-9-carboxy- Δ -tetrahydrocannabinol in human oral fluid by gas chromatography-tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 225-33	3.2	13
69	Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 218-24	3.2	14
68	Current knowledge on cannabinoids in oral fluid. <i>Drug Testing and Analysis</i> , 2014 , 6, 88-111	3.5	61
67	In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis. <i>Analytical and Bioanalytical Chemistry</i> , 2014 , 406, 785-92	4.4	15
66	Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 7269-79	4.4	23
65	11-Nor-9-carboxy- Δ -tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 6019-27	4.4	18
64	Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 4679-89	4.4	29
63	First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. <i>AAPS Journal</i> , 2013 , 15, 1091-8	3.7	67
62	Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 9437-48	4.4	97
61	First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. <i>Clinical Chemistry</i> , 2013 , 59, 1638-48	5.5	80
60	Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers. <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 8451-61	4.4	38
59	Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?. <i>Drug and Alcohol Dependence</i> , 2013 , 130, 68-76	4.9	26
58	Simultaneous quantification of (Δ)-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry. <i>Journal of Chromatography A</i> , 2013 , 1297, 123-30	4.5	37
57	Cannabis effects on driving skills. <i>Clinical Chemistry</i> , 2013 , 59, 478-92	5.5	378
56	Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. <i>Analytical Chemistry</i> , 2013 , 85, 3730-8	7.8	102
55	Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers on per se drugged driving laws. <i>Clinical Chemistry</i> , 2013 , 59, 519-26	5.5	106
54	Changes in smoking patterns during pregnancy. <i>Substance Use and Misuse</i> , 2013 , 48, 513-22	2.2	33
53	Identifying methamphetamine exposure in children. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 823-30	3.2	13

52	Tolerance to effects of high-dose oral Δ^9 -tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. <i>Journal of Analytical Toxicology</i> , 2013 , 37, 11-6	2.9	51
51	Cannabinoids in exhaled breath following controlled administration of smoked cannabis. <i>Clinical Chemistry</i> , 2013 , 59, 1780-9	5.5	68
50	In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. <i>Clinical Chemistry</i> , 2013 , 59, 1108-17	5.5	37
49	Cannabinoid disposition in oral fluid after controlled smoked cannabis. <i>Clinical Chemistry</i> , 2012 , 58, 748-56	5.5	46
48	On-site test for cannabinoids in oral fluid. <i>Clinical Chemistry</i> , 2012 , 58, 1418-25	5.5	38
47	Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis. <i>Clinica Chimica Acta</i> , 2012 , 413, 765-70	6.2	42
46	Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2012 , 413, 1839-47	6.2	49
45	Predictive model accuracy in estimating last Δ^9 -tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. <i>Drug and Alcohol Dependence</i> , 2012 , 125, 313-9	4.9	33
44	Psychomotor performance, subjective and physiological effects and whole blood Δ^9 -tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis. <i>Journal of Analytical Toxicology</i> , 2012 , 36, 405-12	2.9	71
43	Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. <i>Addiction</i> , 2012 , 107, 694-708	4.6	134
42	Cannabinoid stability in authentic oral fluid after controlled cannabis smoking. <i>Clinical Chemistry</i> , 2012 , 58, 1101-9	5.5	51
41	Piezoresistive Microcantilevers-Based Cocaine Biosensors. <i>Sensor Letters</i> , 2012 , 10, 850-855	0.9	11
40	Cannabis in sport: anti-doping perspective. <i>Sports Medicine</i> , 2011 , 41, 949-66	10.6	49
39	Anger, hostility, and aggression as predictors of persistent smoking during pregnancy. <i>Journal of Studies on Alcohol and Drugs</i> , 2011 , 72, 926-32	1.9	28
38	Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. <i>Addiction</i> , 2011 , 106, 499-506	4.6	60
37	Postmortem redistribution of Δ^9 -tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). <i>Forensic Science International</i> , 2011 , 212, 247-51	2.6	31
36	Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration. <i>Analytical and Bioanalytical Chemistry</i> , 2011 , 401, 599-607	4.4	24
35	Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011 , 401, 1273-83	4.4	85

34	Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. <i>Journal of Mass Spectrometry</i> , 2011 , 46, 603-14	2.2	25
33	Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. <i>Clinical Chemistry</i> , 2011 , 57, 66-75	5.5	147
32	Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. <i>Clinical Chemistry</i> , 2011 , 57, 1406-14	5.5	115
31	Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral (9)-tetrahydrocannabinol administration. <i>Clinical Chemistry</i> , 2011 , 57, 1597-606	5.5	27
30	Identifying prenatal cannabis exposure and effects of concurrent tobacco exposure on neonatal growth. <i>Clinical Chemistry</i> , 2010 , 56, 1442-50	5.5	85
29	Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. <i>Clinical Chemistry</i> , 2010 , 56, 1261-9	5.5	37
28	Nicotine and metabolites in meconium as evidence of maternal cigarette smoking during pregnancy and predictors of neonatal growth deficits. <i>Nicotine and Tobacco Research</i> , 2010 , 12, 658-64	4.9	48
27	Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 628-37	3.2	60
26	Effect of hydrolysis on identifying prenatal cannabis exposure. <i>Analytical and Bioanalytical Chemistry</i> , 2010 , 397, 2335-47	4.4	24
25	Simultaneous quantification of nicotine, opioids, cocaine, and metabolites in human fetal postmortem brain by liquid chromatography tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2009 , 393, 1957-65	4.4	26
24	A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. <i>Analytical and Bioanalytical Chemistry</i> , 2009 , 393, 1977-90	4.4	55
23	Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. <i>Addiction</i> , 2009 , 104, 2041-8	4.6	77
22	Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. <i>Journal of Analytical Toxicology</i> , 2009 , 33, 185-9	2.9	55
21	Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. <i>Drug and Alcohol Dependence</i> , 2009 , 105, 24-32	4.9	86
20	Oral fluid testing for drugs of abuse. <i>Clinical Chemistry</i> , 2009 , 55, 1910-31	5.5	298
19	Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. <i>Clinical Chemistry</i> , 2009 , 55, 1188-95	5.5	44
18	Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. <i>Therapeutic Drug Monitoring</i> , 2009 , 31, 769-75	3.2	35
17	Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. <i>Clinical Chemistry</i> , 2008 , 54, 172-80	5.5	37

16	Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. <i>Journal of Analytical Toxicology</i> , 2008 , 32, 562-9	2.9	78
15	Meconium nicotine and metabolites by liquid chromatography-tandem mass spectrometry: differentiation of passive and nonexposure and correlation with neonatal outcome measures. <i>Clinical Chemistry</i> , 2008 , 54, 2018-27	5.5	26
14	Excretion of Delta9-tetrahydrocannabinol in sweat. <i>Forensic Science International</i> , 2008 , 174, 173-7	2.6	44
13	Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. <i>Psychopharmacology</i> , 2007 , 194, 505-15	4.7	121
12	Cannabinoid concentrations in hair from documented cannabis users. <i>Forensic Science International</i> , 2007 , 169, 129-36	2.6	80
11	Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. <i>Journal of Analytical Toxicology</i> , 2007 , 31, 477-85	2.9	65
10	Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 540-4	3.2	37
9	Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. <i>Clinical Chemistry</i> , 2005 , 51, 2289-95	5.5	64
8	Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. <i>Journal of Analytical Toxicology</i> , 2004 , 28, 394-9	2.9	157
7	Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. <i>Clinical Chemistry</i> , 2003 , 49, 1114-24	5.5	31
6	A rapid reusable fiber optic biosensor for detecting cocaine metabolites in urine. <i>Journal of Analytical Toxicology</i> , 1999 , 23, 460-7	2.9	23
5	Urinary excretion half-life of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in humans. <i>Therapeutic Drug Monitoring</i> , 1998 , 20, 570-6	3.2	60
4	Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. <i>Therapeutic Drug Monitoring</i> , 1993 , 15, 527-32	3.2	70
3	Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). <i>Journal of Analytical Toxicology</i> , 1992 , 16, 283-90	2.9	111
2	Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. <i>Journal of Analytical Toxicology</i> , 1992 , 16, 276-82	2.9	356
1	Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. <i>Pharmacology Biochemistry and Behavior</i> , 1990 , 37, 561-5	3.9	101